Is it time for global harmonization of opat drug stability testing frameworks? Great to collaborate with @jasonroberts_pk @b_fekade @CRE_RESPOND @raseaton66 @BSACandJAC & many more - onto the next step! https://t.co/2AsFp3SQGJ
Outpatient Parenteral Antimicrobial Therapy (OPAT) in a Safety-net Hospital: Opportunities for Improvement
✅ Just Accepted
🔓 Open Access
🔗 https://t.co/yWItaxPdji
Definitely team daptomycin for OPAT. Unfortunately, sometimes the copays are still too high for our patients. Especially Medicare patients since Medicare doesn’t cover OPAT well.
Must read! 📖 New SIDP & @Contagion_Live Bench to Bedside 🧪 🧫 👩⚕️ where Drs. @CaraSlaton and Mohamed Hisham Basheer discuss role of non-carbapenem therapy for infected necrotizing pancreatitis!
Available here: https://t.co/2fWNVO8yrr
🆕️🔥The largest real-world, multicenter study of dalbavancin use for Gram-positive BSI @NicholasRebold@IDpharmresearch and many @SIDPharm 🌟s
Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection #IDXposts#DOTS
https://t.co/FOh8iUXInq
Nearly 2x as much treatment failure at 14 days when using cefdinir, compared to cephalexin which has substantially better bioavailability and urinary concentrations in lower UTIs. Makes sense! #downwithcefdinir
Lots of new data coming out in the ID space lately 🔥🔥🔥 check out some of the new articles ⬇️:
SABATO 💉 vs. 💊: https://t.co/ZPXKQ8c3qZ
REGARD-VAP 🫁: https://t.co/U961WQYOoD
#IDXPosts#IDTwitter
Making the EHR work for you - Modifications of an Electronic Health Record System to Improve Tracking and Management of Patients Receiving Outpatient Parenteral Antibiotic Therapy
✅ Just Accepted
🔓 Open Access
🔗 https://t.co/6yxhH9hko5
@ssmunsiffIDdoc
Regular doses of tragedy and still responsible for 3x your normal workload? That was my 2020. Just like most of #IDTwitter. Talking about it was surprisingly therapeutic. Thanks @PaulSaxMD
Go check out our amazing resident posters now until 3 pm! PGY2 ED @BriannaPharmD is working on pharmacist-managed ED culture call back and @Kngodwin20 is improving stewardship for urine cultures to decrease unnecessary treatment of ASB! @FirstHealth#ASHP23
Thanks to @MsSmallsO for highlighting our OPAT study at ASHP Midyear. @tayloreppp was the lead on this study looking at our OPAT program which showed reduced readmissions in patients discharged on vancomycin followed by a pharmacist in OPAT. https://t.co/gOysw3EcsX